Skip to main content

Table 3 Changes in TSQM, 6MWD, medication administration time, and adverse events associated with transitioning from inhaled iloprost to inhaled treprostinil

From: Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension

  Baseline Week 12 Absolute change Standard effect size p
TSQM, mean ± SD
  Effectiveness 62 ± 10 82 ± 16 +20 ± 21 2.0 <0.0001
  Side effects 85 ± 21 85 ± 18 0 ± 22 0 0.97
  Convenience 44 ± 24 83 ± 17 +39 ± 26 1.6 <0.0001
  Global satisfaction 61 ± 23 82 ± 18 +20 ± 24 0.9 <0.0001
6-minute walk distance, mean ± SD, m 395 ± 79 414 ± 84 +16 ± 35 0.2 0.0005
Medication administration time, mean ± SD, min./day
  Gather supplies 21 ± 24 12 ± 11 −9 ± 26 0.4 0.01
  Prepare system 11 ± 8 9 ± 9 −2 ± 12 0.3 0.16
  Inhalation 66 ± 35 13 ± 7 −53 ± 37 1.5 <0.0001
  Clean 21 ± 47 5 ± 4 −16 ± 46 0.3 0.01
  Total time 119 ± 78 39 ± 25 −80 ± 81 1.0 <0.0001
Adverse events, median (IQR)
  Severity-weighted adverse event score - 4.4 ± 2.8 - - -
  1. IQR: interquartile range.
  2. 6-minute walk distance missing for 2 subjects.
  3. Medication administration time missing data for 5 subjects.